Research programme: anti-cancer therapeutics - Proteros biostructures/Janssen
Alternative Names: Covalent Flt3-Cys828 inhibitors - Proteros biostructures; Fms like tyrosine kinase 3 inhibitors - Proteros biostructuresLatest Information Update: 28 Aug 2021
Price :
$50 *
At a glance
- Originator Proteros Biostructures
- Developer Janssen; Proteros Biostructures
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in Germany
- 28 Jul 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Germany
- 27 Jul 2017 Proteros biostructures and Janssen Biotech enter into a research collaboration for developing cancer therapeutics against epigenetic targets